• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同调强放疗增敏递送方法对靶区覆盖和正常组织保护的评估。

Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.

作者信息

Dogan Nesrin, King Stephanie, Emami Bahman, Mohideen Najeeb, Mirkovic Nena, Leybovich Leonid B, Sethi Anil

机构信息

Department of Radiation Oncology, Loyola University Chicago Medical Center, Maywood, IL 60153, USA.

出版信息

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1480-91. doi: 10.1016/s0360-3016(03)01569-4.

DOI:10.1016/s0360-3016(03)01569-4
PMID:14630288
Abstract

PURPOSE

Because of biologic, medical, and sometimes logistic reasons, patients may be treated with 3D conformal therapy or intensity-modulated radiation therapy (IMRT) for the initial treatment volume (PTV(1)) followed by a sequential IMRT boost dose delivered to the boost volume (PTV(2)). In some patients, both PTV(1) and PTV(2) may be simultaneously treated by IMRT (simultaneous integrated boost technique). The purpose of this work was to assess the sequential and simultaneous integrated boost IMRT delivery techniques on target coverage and normal-tissue sparing.

MATERIALS AND METHODS

Fifteen patients with head-and-neck (H&N), lung, and prostate cancer were selected for this comparative study. Each site included 5 patients. In all patients, the target consisted of PTV(1) and PTV(2). The prescription doses to PTV(1) and PTV(2) were 46 Gy and 66 Gy (H&N cases), 45 Gy and 66.6 Gy (lung cases), 50 Gy and 78 Gy (prostate cases), respectively. The critical structures included the following: spinal cord, parotid glands, and brainstem (H&N structures); spinal cord, esophagus, lungs, and heart (lung structures); and bladder, rectum, femurs (prostate structures). For all cases, three IMRT plans were created: (1) 3D conformal therapy to PTV(1) followed by sequential IMRT boost to PTV(2) (sequential-IMRT(1)), (2) IMRT to PTV(1) followed by sequential IMRT boost to PTV(2) (sequential-IMRT(2)), and (3) Simultaneous integrated IMRT boost to both PTV(1) and PTV(2) (SIB-IMRT). The treatment plans were compared in terms of their dose-volume histograms, target volume covered by 100% of the prescription dose (D(100%)), and maximum and mean structure doses (D(max) and D(mean)).

RESULTS

H&N cases: SIB-IMRT produced better sparing of both parotids than sequential-IMRT(1), although sequential-IMRT(2) also provided adequate parotid sparing. On average, the mean cord dose for sequential-IMRT(1) was 29 Gy. The mean cord dose was reduced to approximately 20 Gy with both sequential-IMRT(2) and SIB-IMRT. Prostate cases: The volume of rectum receiving 70 Gy or more (V(>70 Gy)) was reduced to 18.6 Gy with SIB-IMRT from 22.2 Gy with sequential-IMRT(2). SIB-IMRT reduced the mean doses to both bladder and rectum by approximately 10% and approximately 7%, respectively, as compared to sequential-IMRT(2). The mean left and right femur doses with SIB-IMRT were approximately 32% lower than obtained with sequential-IMRT(1). Lung cases: The mean heart dose was reduced by approximately 33% with SIB-IMRT as compared to sequential-IMRT(1). The mean esophagus dose was also reduced by approximately 10% using SIB-IMRT as compared to sequential-IMRT(1). The percentage of the lung volume receiving 20 Gy (V(20 Gy)) was reduced to 26% by SIB-IMRT from 30.6% with sequential-IMRT(1).

CONCLUSIONS

For equal PTV coverage, both sequential-IMRT techniques demonstrated moderately improved sparing of the critical structures. SIB-IMRT, however, markedly reduced doses to the critical structures for most of the cases considered in this study. The conformality of the SIB-IMRT plans was also much superior to that obtained with both sequential-IMRT techniques. The improved conformality gained with SIB-IMRT may suggest that the dose to nontarget tissues will be lower.

摘要

目的

由于生物学、医学以及有时是后勤方面的原因,患者可能先接受三维适形放疗或调强放射治疗(IMRT)来治疗初始治疗体积(PTV(1)),随后对加量体积(PTV(2))进行序贯IMRT加量。在一些患者中,PTV(1)和PTV(2)可同时接受IMRT治疗(同步整合加量技术)。本研究的目的是评估序贯和同步整合加量IMRT技术在靶区覆盖和正常组织保护方面的效果。

材料与方法

选取15例头颈部(H&N)、肺部和前列腺癌患者进行此项对比研究。每个部位包括5例患者。所有患者的靶区均由PTV(1)和PTV(2)组成。PTV(1)和PTV(2)的处方剂量分别为46 Gy和66 Gy(H&N病例)、45 Gy和66.6 Gy(肺部病例)、50 Gy和78 Gy(前列腺病例)。关键结构包括:脊髓、腮腺和脑干(H&N结构);脊髓、食管、肺和心脏(肺部结构);膀胱、直肠、股骨(前列腺结构)。对于所有病例,创建了三个IMRT计划:(1)对PTV(1)进行三维适形放疗,随后对PTV(2)进行序贯IMRT加量(序贯IMRT(1)),(2)对PTV(1)进行IMRT,随后对PTV(2)进行序贯IMRT加量(序贯IMRT(2)),以及(3)对PTV(1)和PTV(2)同时进行同步整合IMRT加量(SIB-IMRT)。根据剂量体积直方图、100%处方剂量覆盖的靶区体积(D(100%))以及最大和平均结构剂量(D(max)和D(mean))对治疗计划进行比较。

结果

H&N病例:与序贯IMRT(1)相比,SIB-IMRT对双侧腮腺的保护更好,尽管序贯IMRT(2)也能提供足够的腮腺保护。平均而言,序贯IMRT(1)的脊髓平均剂量为29 Gy。序贯IMRT(2)和SIB-IMRT的脊髓平均剂量均降至约20 Gy。前列腺病例:接受70 Gy及以上剂量的直肠体积(V(>70 Gy)),SIB-IMRT使其从序贯IMRT(2)的22.2 Gy降至18.6 Gy。与序贯IMRT(2)相比,SIB-IMRT使膀胱和直肠的平均剂量分别降低了约10%和约7%。SIB-IMRT时左、右股骨的平均剂量比序贯IMRT(1)时低约32%。肺部病例:与序贯IMRT(1)相比,SIB-IMRT使心脏平均剂量降低了约33%。与序贯IMRT(1)相比,使用SIB-IMRT时食管平均剂量也降低了约10%。接受20 Gy剂量的肺体积百分比(V(20 Gy)),SIB-IMRT使其从序贯IMRT(1)的30.6%降至26%。

结论

对于相同的PTV覆盖情况,两种序贯IMRT技术在关键结构保护方面均有适度改善。然而,在本研究考虑的大多数病例中,SIB-IMRT显著降低了关键结构的剂量。SIB-IMRT计划的适形性也明显优于两种序贯IMRT技术。SIB-IMRT获得的更好适形性可能意味着非靶组织的剂量会更低。

相似文献

1
Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.不同调强放疗增敏递送方法对靶区覆盖和正常组织保护的评估。
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1480-91. doi: 10.1016/s0360-3016(03)01569-4.
2
The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.头颈部癌调强放射治疗中腮腺保留及生物等效剂量增加的潜力:一项治疗设计研究。
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205. doi: 10.1016/s0360-3016(99)00304-1.
3
Dosimetric comparison of standard three-dimensional conformal radiotherapy followed by intensity-modulated radiotherapy boost schedule (sequential IMRT plan) with simultaneous integrated boost-IMRT (SIB IMRT) treatment plan in patients with localized carcinoma prostate.局限性前列腺癌患者中标准三维适形放疗后序贯调强放疗推量方案(序贯调强放疗计划)与同步整合推量调强放疗(SIB IMRT)治疗计划的剂量学比较
Indian J Urol. 2012 Jul;28(3):300-6. doi: 10.4103/0970-1591.102707.
4
Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.调强适形放疗同步整合加量治疗高危前列腺癌的剂量学优势
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1251-7. doi: 10.1016/j.ijrobp.2004.11.034.
5
Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.方案靶区定义对正常组织 sparing 能力的重要性:眼眶内肿瘤的调强放疗(IMRT)与三维适形放疗(3D-CRT)计划比较
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1540-8. doi: 10.1016/j.ijrobp.2005.04.013.
6
Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.不可切除的非小细胞肺癌治疗中降低毒性和增加剂量的潜力:调强放射治疗(IMRT)、三维适形放疗和选择性淋巴结照射的比较
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):875-90. doi: 10.1016/s0360-3016(03)00743-0.
7
Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol.为一种大分割前列腺癌治疗方案开发同步推量调强放射治疗类解决方案。
Br J Radiol. 2004 May;77(917):377-86. doi: 10.1259/bjr/66104316.
8
Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.同步整合调强放疗加量治疗局部晚期妇科癌症:放射生物学和剂量学考量
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):933-9. doi: 10.1016/j.ijrobp.2004.11.040.
9
Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques.使用脉冲低剂量率输送技术的胰腺癌和前列腺癌调强放射治疗。
Med Dosim. 2014 Winter;39(4):330-6. doi: 10.1016/j.meddos.2014.05.008. Epub 2014 Jul 30.
10
Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer.被动质子治疗与调强放射治疗针对前列腺癌局部加量的计划研究
Radiat Oncol. 2015 Oct 24;10:213. doi: 10.1186/s13014-015-0522-5.

引用本文的文献

1
Impact of Postoperative Radiation Therapy Delay and Treatment Facility Location on Survival in Head and Neck Cancer Patients.术后放疗延迟及治疗机构地点对头颈部癌患者生存的影响
Head Neck. 2025 Jul;47(7):1807-1815. doi: 10.1002/hed.28092. Epub 2025 Jan 31.
2
Long-term Prospective Comparative Analysis of Ototoxic and Survival Outcomes of Sequential Boost and Simultaneous Integrated Boost of Volumetric Modulated Arc Therapy for Head-Neck Carcinomas.头颈部癌容积调强弧形放疗序贯推量与同步整合推量的耳毒性及生存结果的长期前瞻性比较分析
Turk Arch Otorhinolaryngol. 2025 Jan 10;62(3):101-112. doi: 10.4274/tao.2024.2023-10-10.
3
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
同步整合加量(SIB)的中度低分割放疗用于(极)高危前列腺癌的5年生存率和毒性的前瞻性研究结果
Clin Transl Radiat Oncol. 2023 Nov 17;44:100702. doi: 10.1016/j.ctro.2023.100702. eCollection 2024 Jan.
4
Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost.口咽癌的剂量递增:同期整合推量与近距离放疗推量的比较。
Radiat Oncol. 2023 Apr 7;18(1):65. doi: 10.1186/s13014-023-02256-x.
5
Introducing new plan evaluation indices for prostate dose painting IMRT plans based on apparent diffusion coefficient images.基于表观扩散系数图像的前列腺剂量画象调强放疗计划新评价指标的引入。
Radiat Oncol. 2022 Nov 23;17(1):193. doi: 10.1186/s13014-022-02163-7.
6
Carbon Ion Radiotherapy Induce Metabolic Inhibition After Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer.碳离子放疗在功能成像引导下对前列腺癌进行同步整合加量后诱导代谢抑制
Front Oncol. 2022 Jul 22;12:845583. doi: 10.3389/fonc.2022.845583. eCollection 2022.
7
Treatment of intracranial neoplasia in dogs using higher doses: A randomized controlled trial comparing a boosted to a conventional radiation protocol.使用更高剂量治疗犬颅内肿瘤:比较增强方案与常规放疗方案的随机对照试验。
J Vet Intern Med. 2022 Jul;36(4):1353-1364. doi: 10.1111/jvim.16472. Epub 2022 Jun 30.
8
Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.晚期食管鳞状细胞癌患者确定性同步整合加量放疗与常规分割调强放疗的比较:一项倾向评分匹配分析
Front Oncol. 2021 Jun 21;11:618776. doi: 10.3389/fonc.2021.618776. eCollection 2021.
9
A randomized prospective study comparing acute toxicity, compliance and objective response rate between simultaneous integrated boost and sequential intensity-modulated radiotherapy for locally advanced head and neck cancer.一项比较同步整合加量放疗与序贯调强放疗治疗局部晚期头颈癌的急性毒性、依从性和客观缓解率的随机前瞻性研究。
Radiat Oncol J. 2021 Mar;39(1):15-23. doi: 10.3857/roj.2020.01018. Epub 2021 Mar 18.
10
Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era.比较调强放疗时代 UICC/AJCC 第 7 版和第 8 版鼻咽癌分期系统。
BMC Cancer. 2021 Mar 30;21(1):327. doi: 10.1186/s12885-021-08036-8.